CNAT Conatus Pharmaceuticals Inc.
1.98
-0.06 -3%
Previous Close
2.04
Open
2.05
Price To Book
3.97
Market Cap
65777713
Shares
33,144,066
Volume
304,206
Short Ratio
Av. Daily Volume
914,896
NewsSee all news
- Conatus (CNAT) Completes Enrollment in Phase II NASH Study
- Conatus Announces Completion of Enrollment in ENCORE-LF Phase 2b Clinical Trial of Emricasan in Patients with Decompensated NASH Cirrhosis
- Today's Research Reports on Trending Tickers: Voyager Therapeutics and Conatus Pharmaceuticals
- Can GW Pharmaceuticals (GWPH) Deliver a Beat in Q1 Earnings?
- Conatus Pharmaceuticals Announces Publications Expanding on Previously Reported Results from Completed Phase 2 NAFLD-NASH, Portal Hypertension and Liver Cirrhosis Clinical Trials
SEC filingsSee all SEC filings
- SC 13G - Statement of acquisition of beneficial ownership by individuals 19576517
- 8-K - Current report 181218888
- 8-K - Current report 181218887
- 10-Q - Quarterly report [Sections 13 or 15(d)] 181154859
- 8-K - Current report 181153705
Drug Information
Drug catalyst information is displayed when you hover over the stage bar graph.
Emricasan
NASH cirrhosis - ENCORE-LF trial
Emricasan
NASH cirrhosis - ENCORE-PH trial
Phase 2 topline data released Jan 2015
Emricasan
Acute-on-Chronic Liver Failure (ACLF)
Phase 2b data released April 4, 2018. Primary endpoint not met.
Emricasan
Liver fibrosis post-orthotopic liver transplant due to Hepatitis C virus infection (HCV-POLT)
Phase 2 topline data released early January 2016
Emricasan
Liver Cirrhosis
Phase 2 data released September 2015.
Emricasan
Portal Hypertension
Latest News
- Conatus (CNAT) Completes Enrollment in Phase II NASH Study
- Conatus Announces Completion of Enrollment in ENCORE-LF Phase 2b Clinical Trial of Emricasan in Patients with Decompensated NASH Cirrhosis
- Today's Research Reports on Trending Tickers: Voyager Therapeutics and Conatus Pharmaceuticals
- Can GW Pharmaceuticals (GWPH) Deliver a Beat in Q1 Earnings?
- Conatus Pharmaceuticals Announces Publications Expanding on Previously Reported Results from Completed Phase 2 NAFLD-NASH, Portal Hypertension and Liver Cirrhosis Clinical Trials
- Conatus (CNAT) Focuses on Developing NASH Candidate Emricasan
- The Zacks Analyst Blog Highlights: Gilead Sciences, Conatus Pharmaceuticals, Biogen, Ionis Pharmaceuticals and Exelixis
- Biotech Stock Roundup: Gilead to Get New CEO, Biogen In-Licenses Candidate
- The Daily Biotech Pulse: FDA Nod For Roche, Bristol-Myers Hikes Dividend, 2 Biotechs To Debut
- Conatus' Emricasan Misses Primary Endpoint in Mid-Stage Study
- Shares of Conatus Pharmaceuticals plummet over 50% after Phase 2 trial fails to meet primary endpoint
- Today's Research Reports on Trending Tickers: Conatus Pharmaceuticals and Exelixis
- Conatus Announces Results from ENCORE-PH Phase 2b Clinical Trial in NASH Cirrhosis
- When Will Conatus Pharmaceuticals Inc (NASDAQ:CNAT) Become Profitable?
- Do Options Traders Know Something About Conatus (CNAT) Stock We Don't?
- Edited Transcript of CNAT earnings conference call or presentation 1-Nov-18 8:30pm GMT
- Today’s Research Reports on Stocks to Watch: Conatus Pharmaceuticals and Titan Pharmaceuticals
SEC Filings
- SC 13G - Statement of acquisition of beneficial ownership by individuals 19576517
- 8-K - Current report 181218888
- 8-K - Current report 181218887
- 10-Q - Quarterly report [Sections 13 or 15(d)] 181154859
- 8-K - Current report 181153705
- 8-K - Current report 181069022
- 424B5 - Prospectus [Rule 424(b)(5)] 18988568
- 10-Q - Quarterly report [Sections 13 or 15(d)] 18988327
- 8-K - Current report 18984758
- SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 18945942